Canadians across the country mark Remembrance Day
Today Canadians will remember and honour the sacrifice of men and women in uniform who gave their lives in service of the country's values and principles.
New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe the medicine is over four years of use.
The analyses 鈥 of a trial called Select, whose results last year that Wegovy significantly reduced heart risk in addition to helping with weight loss 鈥 also suggest that the drug may protect the heart in ways beyond weight loss alone, researchers said, raising new questions about how the wildly popular medicines in this drug class should be used 鈥 and covered by insurers.
鈥淭he implications are profound,鈥 said , a cardiologist and scientist at Yale University and Yale New Haven Hospital who was not involved in the research, noting that a second this week showed a similar finding for heart failure. 鈥淲e have not encountered a drug with such a breadth of heart benefits.鈥
More than 25,000 people in the U.S. are starting Wegovy every week, drugmaker Novo Nordisk this month. And in a KFF released Friday, 6 per cent of respondents said they were currently using a drug in this class, known as GLP-1 receptor agonists. That translates to more than 15 million Americans.
One important question about these blockbuster medicines is how widely 鈥 and how long 鈥 they鈥檝e been studied. The Select trial, which was funded by Novo Nordisk, last year that Wegovy reduced the risk of a heart attack, stroke or heart-related death by 20 per cent in people with existing cardiovascular risk with obesity or who are overweight. It included more than 17,600 people from 41 countries between 2018 and 2021 and followed them for several years.
Researchers have continued to mine the data, and the new analyses, presented Monday at the and published in the journal , show results for people taking Wegovy as long as four years. Here are some major takeaways:
Weight loss continued for more than a year
The analysis showed an average weight loss of just over 10 per cent for people who used semaglutide, the active ingredient in Wegovy, compared with 1.5 per cent for study participants who got a placebo. The researchers, led by Dr. Donna Ryan of Pennington Biomedical Research Center in Baton Rouge, Louisiana, noted that the trend showed that participants on the medication typically lost weight for about 65 weeks, or a year and three months, before reaching a plateau.
A showed even greater average weight loss for Wegovy: about 15 per cent on average over 68 weeks, compared with 2.4 per cent for people who got a placebo. The researchers on the new analysis noted that, in addition to some differences in the people who enrolled in each trial, the previous study was designed specifically for weight loss and included more structured lifestyle interventions about diet and exercise compared with the Select trial, which was designed to test whether the drug prevented cardiac events.
It was sustained for up to four years
The results showed that the 10 per cent average weight loss for people using Wegovy was sustained for up to 208 weeks, or four years.
Patients stayed on the medicine while they sustained the weight loss. Other studies have shown that many people regain weight after stopping the drugs, including one in December from Novo Nordisk competitor Eli Lilly: People using the GLP-1 drug Zepbound, which uses the active ingredient tirzepatide and targets a second hormone called GIP, lost an average of 21 per cent of their body weight over 36 weeks. The participants were then split into two groups, and those who stayed on the medicine lost an additional 5.5 per cent of their body weight, while those who unknowingly switched to a placebo regained 14 per cent of their weight.
However, not everybody regained so much weight. The study also looked at how many people maintained at least 80 per cent of the weight loss after the initial 36 weeks, and while many more who continued on the drug did 鈥 almost 90 per cent - almost 17 per cent of people who were switched to a placebo maintained that much weight loss without the drug.
Results vary for everyone
In the new analysis, the researchers reported that after two years, about 68 per cent of people taking Wegovy had lost at least 5 per cent of their body weight, while 21 per cent of people on a placebo did. Almost 23 per cent of people on Wegovy lost at least 15 per cent of their body weight, compared with 1.7 per cent on a placebo. And almost 5 per cent of people on the drug lost more than 25 per cent of their body weight, compared with 0.1 per cent on placebo, showing that the top-line findings from studies are just averages; everyone has a different experience with medicines.
No safety surprises out to four years
Overall, more people on Wegovy decided to stop participating in the trial because of side effects than people who got a placebo: 17 per cent of those on the drug versus 8 per cent on placebo, a result that was reported. And the side effects were ones that are widely known with these medicines: mainly gastrointestinal disorders like nausea, diarrhea, vomiting and constipation, which usually affected people in the first few months of the study as the dose of the medicine increased.
The researchers noted that there were no new safety signals seen in the latest analyses. Acute pancreatitis, or inflammation of the pancreas, wasn鈥檛 seen at a higher rate among those on Wegovy than placebo, although gallbladder disorders like gallstones were: 2.8 per cent for people on Wegovy, compared with 2.3 per cent for people on placebo. Both are included in warnings in the drug鈥檚 because they鈥檇 been seen previously in trials.
Benefits beyond weight loss
A key question when the full results of the Select trial were initially presented was whether the 20 per cent reduction in heart risk was driven by weight-loss alone or some other protective effect of the drug. The new suggests that there is something else at play.
That鈥檚 because the reduction in risk of heart attack or other events was seen even in people using Wegovy who didn鈥檛 lose weight.
鈥淵ou probably don鈥檛 even need to lose weight to get the cardiovascular benefit鈥 with semaglutide and similar medicines, said Dr. Daniel Drucker, a pioneer of research into GLP-1 at the University of Toronto who wasn鈥檛 involved in the new analyses. 鈥淭hat鈥檚 because that鈥檚 what GLP-1 does: It鈥檚 cardio-protective, at least in animals, independent of whether or not you have diabetes, independent of whether you have obesity, and you don鈥檛 require weight loss 鈥 it鈥檚 not the whole story.鈥
An led by of University College London found that the reduction in major adverse cardiovascular events in the study for those on Wegovy, compared with placebo, was similar among people who lost 5 per cent or more of their body weight and those who lost less than that or even those who gained weight.
鈥淭his suggests alternative mechanisms of improved cardiovascular outcome beyond reduction in adiposity,鈥 or body fat, the researchers concluded.
A separate study published about heart failure, for which Wegovy has a major benefit, suggested the same thing, Krumholz said.
鈥淭hese two studies show that these anti-obesity medications are also heart-health drugs,鈥 he wrote in an email. 鈥淭he benefits to the heart for people with established cardiovascular disease or a certain type of heart failure occur regardless of the amount of weight loss.鈥
A benefit from reducing inflammation
Drucker suspects that GLP-1 drugs provide these kinds of benefits by reducing inflammation.
鈥淲e can鈥檛 ignore the reduction in blood pressure or triglycerides, and the reduction in body weight must help a little bit, and glucose must help a little as well,鈥 he said.
But based on research, he said, 鈥渙ne of my favorite theories is inflammation, because we know that people with cardiovascular disease do have increased inflammation in their blood vessels and in the heart.鈥
Drucker said studies have shown that GLP-1 drugs tamp down harmful inflammation, which his lab is studying. He even noted that he receives communications from people with conditions like Covid-related brain fog, ulcerative colitis and arthritis 鈥 driven by inflammation 鈥 who think their symptoms have improved while using GLP-1 medicines. Those links would need to be borne out in clinical studies to be considered definitive.
The results in the Select trial, he said, raise the question of whether people who don鈥檛 have obesity or aren鈥檛 overweight but who have had a heart attack or stroke could benefit from taking a drug like Wegovy to prevent another event 鈥 another thing that would need to be studied.
And, Drucker said, the results suggest that insurers should cover the medicines, which cost about $1,000 per month or more without it, more widely.
鈥淲e probably really need to rethink these criteria for reimbursing the medicines, because they are going to be helpful in terms of actually improving health and saving lives and saving health care dollars in people with obesity and heart disease even without much weight loss,鈥 he said. 鈥淵ou don鈥檛 even need to lose weight to have a reduction in heart attack, strokes and death.鈥
Today Canadians will remember and honour the sacrifice of men and women in uniform who gave their lives in service of the country's values and principles.
U.S. President-elect Donald Trump says that Tom Homan, his former acting U.S. Immigration and Customs Enforcement director, will serve as "border czar" in his incoming administration.
Researchers are uncovering deeper insights into how the human brain ages and what factors may be tied to healthier cognitive aging, including exercising, avoiding tobacco, speaking a second language or even playing a musical instrument.
Since the U.S. Supreme Court鈥檚 2022 Dobbs decision eliminated the federal right to abortion, miscarriage management has become trickier and in some cases, deadlier.
The union representing some 1,200 dockworkers at the Port of Montreal has overwhelmingly rejected a deal with their employers association.
It was the first time that Canadian UN peacekeeper Michelle Angela Hamelin said she came up against the raw emotion of a people so exasperated with their country's predicament.
Applause erupted over and over at the Canada Life Centre in Winnipeg Sunday as the son of Murray Sinclair, a former judge, senator and chair of the Truth and Reconciliation Commission into residential schools, spoke about his father.
A children's book written by British celebrity chef Jamie Oliver has been withdrawn from sale after it was criticized for causing offense to Indigenous Australians.
A man who was critically injured in a police-involved shooting in Hamilton late Sunday afternoon has died in hospital, says the province鈥檚 police watchdog.
A congestion crisis, a traffic nightmare, or unrelenting gridlock -- whatever you call it, most agree that Toronto has a congestion problem. To alleviate some of the gridlock, the Ontario government has announced it plans to remove bike lanes from three major roadways.
For the second year in a row, the 鈥楪ift-a-Family鈥 campaign is hoping to make the holidays happier for children and families in need throughout Barrie.
Some of the most prolific photographers behind CTV Skywatch Pics of the Day use the medium for fun, therapy, and connection.
A young family from Codroy Valley, N.L., is happy to be on land and resting with their newborn daughter, Miley, after an overwhelming, yet exciting experience at sea.
As Connor Nijsse prepared to remove some old drywall during his garage renovation, he feared the worst.
A group of women in Chester, N.S., has been busy on the weekends making quilts 鈥 not for themselves, but for those in need.
A Vancouver artist whose streetside singing led to a chance encounter with one of the world's biggest musicians is encouraging aspiring performers to try their hand at busking.
Ten-thousand hand-knit poppies were taken from the Sanctuary Arts Centre and displayed on the fence surrounding the Dartmouth Cenotaph on Monday.
A Vancouver man is saying goodbye to his nine-to-five and embarking on a road trip from the Canadian Arctic to Antarctica.